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Over 30,000 autologous hematopoietic cell trans-
plants (HCT) have been performed yearly during the
past decade. With improvement in supportive care,
few patients succumb to early treatment complications;
hence,moreattention isbeingpaid tocausesof late com-
plications and death. However, interpretation of the
data that exist is difficult as the definition of ‘‘late’’ varies
by study, as does the patient population, underlying dis-
eases, HCT mobilization and conditioning regimens,
stem cell sources, and duration of follow-up (Table 1).
Most importantly, the methods used to estimate the in-
cidence of late complications over time are different or
are not explained in sufficient detail. Some studies report
relative risk or standardized mortality compared with
the general population. Other studies report an acturial
estimate (which ignores competing risks and thus may
overestimate the incidence), whereas others report cu-
mulative incidence calculations.LATE EFFECTS
In 2005, Bhatia et al. [1] reported results of the first
major study directed at understanding the causes of late
mortality in patients who had survived 2 or more years
following transplantation. The median age at time of
HCTwas 36.5 years. The majority of patients received
a cyclophosphamide (Cy), etoposide, total body irradi-
ation (TBI) conditioning regimen. With a median
follow-up of 7.6 years, the cohort was at a 13-fold in-
creased risk for late death (reported as standardized
mortality ratio 5 13.0) when compared with the
general population.Themost common cause of nonre-Division of Hematology, Oncology and Transplantation,
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Additional causes of late death included cardiac
toxicity, pulmonary complications, and other sequela
including infections.NRMwas increased after carmus-
tine and with use of peripheral blood stem cells (PBSC)
as the graft source.
Researchers at theUniversity ofMinnesota studied
new malignancies after HCT in 1193 children and
adults [2]. The majority of patients received a TBI-
based conditioning regimen. With a median follow-
up of 5 years, malignancies occurred in 55 (4.6%)
patients. For the entire cohort, the cumulative inci-
dence of therapy-related myelodysplastic syndrome/
acute myelogenous leukemia (t-MDS/AML) plateaued
by 10 years post-HCT; in contrast, the risk of develop-
ing solid tumors continued to increased even 20 years
after transplant. For t-MDS/AML, there was a trend
toward a higher risk in patients who were older than
35 years at time of HCT, and the risk was higher in pa-
tients who received PBSC as their stem cell source.
Ita¨la¨ et al. [3] reported late (over100days fromHCT)
complications for a cohort of 1482 adult patients. NRM
was observed in 68 patients (4.6%). The most common
causes of NRM were second malignancies, infections,
and cardiac events. Infections occurred a median of
28 months from transplant. The risk of NRM was
comparable in patients who received TBI versus
chemotherapy-only-based conditioning regimens.
Several smaller studies have also contributed to our
current understanding of late complications and causes
of death in adult patients with lymphoma [4-6]. Andre
et al. [4] matched each grafted patient with 3 conven-
tionally treated controls on age, gender, clinical stage,
B symptoms, and time at risk. The majority of patients
received BEAM (carmustine, etoposide, cytosine
arabinoside, melphalan [Mel]) conditioning for HCT.
The 5-year cumulative incidence rate of second can-
cers was 8.9%. Solid tumors were more frequent in
grafted than in control patients, although the inci-
dence of t-MDS/AML was similar in the 2 groups.
Lavoie et al. [5] reported the long-term outcome in
the first 100 adult patients with Hodgkin lymphoma
(HL) treated in Vancouver. All patients received
Cy, carmustine, etoposide 6 cisplatin conditioning.
The median time to development of a second cancer21
Table 1. Late Complications after Hematopoietic Cell Transplantation
Author and Year n Primary Tumor(s) Complications Risk Factors
Bhatia et al. 2005 854 AML t-MDS/AML (4.7%)
ALL solid tumors (2.3%)
NHL NHL (0.2%) carmustine, PBSC
HL cardiac (0.7%)
pulmonary (0.6%)
other (3.9%)
Baker et al. 2003 1193 CML t-MDS/AML (2.5%)age age >35 years, PBSC
AML solid tumors (1.7%)
NHL PTLD (0.1%)
HL CML (0.1%)
Neuroblastoma HL (0.1%)
Breast cancer
Ita¨la¨ et al. 2006 1482 NHL t-MDS/AML (0.8%) NR
MM solid tumors (0.7%)
Breast cancer PTLD (0.1%)
HL infections (1.5%)
CLL cardiac (0.9%)
Andre et al. 1998 467 HL t-MDS/AML (1.7%) age 5 40 years
solid tumors (0.7%) PBSC
NHL (0.4%)
Lavoie et al. 2005 100 HL t-MDS/AML (2%) NR
solid tumors (1%)
NHL (4%)
endocrine (32%)
infections (10%)
cardiac (5%)
Ruiz-Soto et al. 2005 439 NHL t-MDS/AML (0.5%) previous disease recurrence
solid tumors (1.4%) prior lines
chemotherapy, age
pulmonary (1.1%)
ALL indicates acute lymphoblastic leukemia; CLL, chronic lymphocytic leukemia; CML, chronic myelogenous leukemia; HCT, hematopoietic cell
transplantation; HL, Hodgkin lymphoma; MM, multiple myeloma; NHL, non-Hodgkin lymphoma; NR, not reported; PTLD, post-transplant lymphopro-
liferative disorder; PBSC, peripheral blood stem cells; t-MDS/AML, therapy related myelodysplastic syndrome/acute myelogenous leukemia.
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of 9%. Other late effects included endocrine abnor-
malities (hypogonadism and hypothyroidism), unusual
infections, and cardiac disease (majority of these pa-
tients had received prior mediastinal irradiation).
Ruiz-Soto and colleagues [6] reported adverse events
occurring more than 30 days after HCT. Nine subse-
quent malignancies were diagnosed with a 3-year cu-
mulative incidence of 3.7%. Five patients developed
pulmonary fibrosis a median of 3 years following
HCT. Previous disease recurrence, prior lines of che-
motherapy before HCT, and increasing age were risk
factors for developing a second tumor.
Majhail et al. [7] reported the prevalence of self-
reported nonmalignant late effects in 276 adult survi-
vors of autologous HCT for lymphoma. Compared
to siblings, HCT survivors reported a significantly
higher frequency of cataracts, dry mouth, hypothy-
roidism, bone impairments, congestive heart failure,
exercise-induced shortness of breath, and neurosen-
sory impairments. In a study by Choi and colleagues
[8] of 562 patients, the cumulative incidence of delayed
chronic kidney disease was 3.8% at 5 years, with
advanced age and a primary diagnosis of multiple
myeloma (MM) being risk factors.Several studies address the long-term complica-
tions in children. The European Blood and Marrow
Transplantation Acute Leukemia Working Party
reported outcomes of 387 children who underwent
transplantation for AML in first remission [9]. Of
patients surviving at least 18 months, 33% experienced
at least 1 late sequelae, including impairment of
growth velocity, hypothyroidism, and hypogonadism.
Common long-term complications in children with
neuroblastoma following TBI 1 chemotherapy
HCT conditioning include growth and pubertal fail-
ure, hearing impairment, orthopedic complications,
renal impairment, and thyroid abnormalities [10].
In summary, the most common cause of NRM is
a second malignancy, with t-MDS/AML and solid
tumors being seen most frequently. The risk for t-
MDS/AML appears to be highest within the first de-
cade following HCT; in contrast, patients remain at
risk of solid tumors for at least 20 years. Several reports
have described an increased risk for late infectious
complications. Fatal cardiac, pulmonary, and kidney
disease are uncommon events. Nonfatal late effects
include cataracts, hypothyroidism, and neurosensory
impairments; in addition, children experience growth
and developmental failure. Investigators should make
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dence rates to facilitate comparisons between studies.IS THE TRANSPLANT TO BLAME?
Second malignancies
Following the initial reports of post autologous
HCT t-MDS/AML in 1994, subsequent studies
reported actuarial or cumulative incidences ranging
from 1% to 24% (reviewed in [11]). Some investigators
noted that pre-HCT abnormalities not detected by
cytogenetic analysis could be detected by fluorescein
in situ hybridization (FISH), lending credence to the
hypothesis that pre-HCT therapy was to blame.
Others noted that PBSC as the graft source and use
of TBI-based preparative regimens increased the risk
of t-MDS/AML.
Results from 2 prospective studies are supportive
of a strong association of large, cumulative doses of
alkylating agents with the development of t-MDS/
AML. The German Low Grade Lymphoma Study
Group reported results from a prospective trial that
randomized 440 patients following alkylator-based
induction therapy to autologous HCT versus inter-
feron alpha maintenance for indolent lymphoma
[12]. The 5-year cumulative incidence for secondary
hematologic neoplasias after HCT was significantly
higher at 3.8% compared to the interferon arm of
0.0%. Similarly, in a prospective study from Arkansas
of patients transplanted for MM, all patients who
developed t-MDS/AML belonged to a subgroup of
patients initially treated with more than 1 cycle of an
alkylator-based chemotherapy regimen, whereas those
patients proceeding to transplant after only 1 cycle did
not develop leukemia [13].
Several groups have reported that HCT alone is
not associated with an increased risk of t-MDS/
AML. Harrison et al. [14] reported a retrospective
comparative study of 4576 patients with HL 595
patients had received high-dose BEAM chemotherapy
with autologous HCT. They identified 3 pre-HCT
risk factors for t-MDS/AML: quantity of prior ther-
apy, exposure to MOPP (mechlorethamine, vincris-
tine, prednisone, procarbazine), and lomustine
chemotherapy. Likewise, the Vancouver group com-
pared the incidence of second malignancies among
patients with HL treated with high-dose chemother-
apy conditioning and autologous HCT compared
with patients who received conventional chemother-
apy alone and did not see an increased risk with
HCT [15]. Krishman et al. [16] used a retrospective
cohort and a nested case-controlled design study to as-
sess risk factors for t-MDS/AML in 612 HL andNHL
patients. Stem cell priming with etoposide resulted in
a 12.3-fold increased risk of t-MDS/AML with11q23/21q22 abnormalities. Multivariate analysis
revealed an association between prior irradiation and
the risk of t-MDS/AML, but failed to reveal any
associations with HCT.
The Arkansas group reported a low incidence of
cytogenetically defined MDS following auto HCT
for MM [17]. The 10 year estimated actuarial inci-
dence was 1%, and was linked to a CD34 yield of
less than 3  104/kg and need for more than 2 apher-
esis procedures, suggesting damage to hematopoietic
stem cells that antedated HCT. Furthermore, patients
who received post-HCT consolidation chemotherapy
had late-onset MDS, suggesting possible post-HCT
stem cell damage.
What conclusions can be drawn from these stud-
ies? Compared to the general population, it is clear
that patients undergoing autologous HCT are at an
increased risk of developing second cancers, and that
there is a strong association with high, cumulative
doses of alkylator therapy. Transplantation of col-
lected stem cells with occult chromosomal damage
from prior therapies or priming chemotherapy may
lead to outgrowth post-HCT of preleukemic clones.
Other factors, including TBI, have been identified as
risk factors in some studies but not in others, suggest-
ing that most likely pre-HCT therapies, priming che-
motherapy, HCT conditioning regimens, post-HCT
therapies as well as underlying immunologic defi-
ciencies impairing cancer surveillance all contribute
to the development of post-HCT malignancies.
Other Late Complications
In an analogous manner, other late complications
of autologous HCT are most likely the culmination
of numerous factors. Pretransplant comorbidities, un-
derlying disease, pre-HCT chemo- and radiotherapy,
genetics, age, life style (including smoking, alcohol
use, and diet) as well as HCT and post-HCT therapies
most likely all have an impact on whether or not a pa-
tient is more susceptible to infections or suffers from
late organ toxicity.MINIMIZING LATE EFFECTS
With the knowledge that the etiology of late com-
plications post HCT is multifactorial, steps must be
taken to minimize the potential for late effects when
developing and implementing a therapeutic plan.
Well-designed prospective trials have enabled physi-
cians to move to transplant earlier in the course of a
disease for certain high risk patients, thus limiting
pre-HCT therapies. For patients with primary refrac-
tory disease who need additional salvage therapy
prior to transplant, minimizing exposure to alkylating
agents would be prudent if equally effective alterna-
tives are available. Non-TBI conditioning regimens
24 Biol Blood Marrow Transplant 15:21-24, 2009L. J. Burnsshould be considered when considered equivalent in
outcomes to TBI-based regimens. Although such
efforts may reduce the risks, patients will most likely
continue to develop second malignancies and late
complications. Children should undergo evaluation
by endocrinologists familiar with the side effects of
HCT on growth, puberty, and endocrine abnormali-
ties. Likewise, transplant physicians must be cognizant
of the increased risk for t-MDS/AML in the first few
years and for solid tumors for over 20 years following
HCT, counsel patients appropriately, and ensure on-
going follow-up. In addition to second malignancies,
prudent observation and testing for infections, cardio-
pulmonary, and renal abnormalities inHCT recipients
should be life long.ACKNOWLEDGMENTS
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